If you are a long term shareholder, what does today's pricing action matter. If you know you have the goods, sit tight and wait. Dan is advancing the product through clinical trials, should be starting a Phase III trial very soon, other trials going on are sponsored and paid for by other groups, they are taking shares in lieu of cash, and we are just awaiting more trial results. The further down the road we get, the closer we are to clinching either a deal with a big Bio player or having a product on our own. When Aratana will generate revenue from the Canine Osteosarcoma, that will help to give us needed cash and additionally demonstrate efficacy of our product.
Dan has done way better than Tom Moore and in time will do even more for us shareholders. There will be ups and downs in the share price, but we are much closer now to approval than we were 7 years ago. The naysayers will always be out there, but Dan is heading in the right direction and I think a deal is right around the corner.